1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2016

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2016" provides an overview of Bronchopulmonary Dysplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchopulmonary Dysplasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Bronchopulmonary Dysplasia Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Bronchopulmonary Dysplasia 31
Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial 31
Clinical Trial Profile Snapshots 32
Appendix 92
Abbreviations 92
Definitions 92
Research Methodology 93
Secondary Research 93
About GlobalData 94
Contact Us 94
Disclaimer 94
Source 95

List of Tables
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials, G7 Countries (%), 2016* 15
Bronchopulmonary Dysplasia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Bronchopulmonary Dysplasia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials, E7 Countries (%), 2016* 18
Bronchopulmonary Dysplasia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Bronchopulmonary Dysplasia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Bronchopulmonary Dysplasia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials, G7 Countries (%), 2016* 15
Bronchopulmonary Dysplasia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Bronchopulmonary Dysplasia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Bronchopulmonary Dysplasia to Respiratory Clinical Trials, E7 Countries (%), 2016* 18
Bronchopulmonary Dysplasia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Bronchopulmonary Dysplasia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Bronchopulmonary Dysplasia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Bronchopulmonary Dysplasia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Bronchopulmonary Dysplasia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 93

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze the challenges and opportunities of developing breakthrough therapies, compare difference fast track drug development approaches and the potential risk and rewards of gaining ...


Download Unlimited Documents from Trusted Public Sources

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Antiviral and Therapy Market in Uganda

  • March 2017
    14 pages
  • HIV Antiviral  

    Antiviral  

    Therapy  

  • Uganda  

View report >

Therapy and Antiviral Market

  • March 2017
    11 pages
  • Therapy  

    Antiviral  

    Hepatitis Treat...  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.